Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.
Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-α (HIF1-α) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-α stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.
The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.
|Randall Johnson, PhD||Oxford University|
|Peter Campochiaro, MD||Johns Hopkins School of Medicine|
|Dietmar Vestweber, PhD||Max Planck Institute|
|Chris Kontos, MD||Duke University School of Medicine|
|Sean Colgan, PhD||University of Colorado Denver|
|Susan Quaggin, MD||Northwestern University Feinberg School of Medicine|
Clincal Advisory Board - Opthalmology
|Peter Campochiaro, MD||Wilmer Eye Institute, Johns Hopkins School of Medicine|
|Jeffrey Heier, MD||Ophthalmic Consultants of Boston|
|Tom Gardner, MD||Kellogg Eye Institute, University of Michigan|
|Eugene Ng, MD, MBA||Hawaii Retina, Honolulu, HI|
|Director||Campbell Murray, M.D., Novartis Venture Fund|
|Director||Dr. Lauren Silverman, Novartis Venture Fund|
|Director||Muneer Satter, Satter Investment Management LLC|
|Director||Paul Weiss, Ph.D., Venture Investors, LLC|
|Director||John Rice, Ph.D., Triathlon Medical Ventures|
|Director||Anupam Dalal, M.D., Kearny Venture Partners|
|Director||Joseph Gardner, Ph.D., Akebia Therapeutics, Inc.|
|Director||Duane Nash, M.D., J.D., M.B.A., Vital Therapies, Inc.|
|Director||Adrienne L. Graves, Ph.D., Board Member at the American Society for Cataract & Refractive Surgery Foundation, Glaucoma Research Foundation, Advisory Board Member at The Foundation of the American Academy of Ophthalmology|